[1]刘应红,罗 波,张宗霞,等.铝碳酸镁联合三联疗法治疗幽门螺杆菌阳性消化性溃疡疗效及对患者幽门螺杆菌根除率及Treg/Th17平衡的影响[J].陕西医学杂志,2023,52(5):591-595.[doi:DOI:10.3969/j.issn.1000-7377.2023.05.022]
　LIU Yinghong,LUO Bo,ZHANG Zongxia,et al.Effects of hydrotalcite combined with triple therapy on helicobacter pylori eradication rate and Treg/Th17 balance in HP-positive peptic ulcer[J].,2023,52(5):591-595.[doi:DOI:10.3969/j.issn.1000-7377.2023.05.022]
点击复制

铝碳酸镁联合三联疗法治疗幽门螺杆菌阳性消化性溃疡疗效及对患者幽门螺杆菌根除率及Treg/Th17平衡的影响
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
52
期数:
2023年5期
页码:
591-595
栏目:
药物与临床
出版日期:
2023-05-05

文章信息/Info

Title:
Effects of hydrotalcite combined with triple therapy on helicobacter pylori eradication rate and Treg/Th17 balance in HP-positive peptic ulcer
作者:
刘应红1; 罗 波2; 张宗霞1; 许 婷1
(1.成都上锦南府医院消化内科,四川 成都 611730; 2.巴中市中心医院消化中心,四川 巴中 636000)
Author(s):
LIU Yinghong; LUO Bo; ZHANG Zongxia; XU Ting
(Department of Gastroenterology,Chengdu Shangjin Nanfu Hospital,Chengdu 611730,China)
关键词:
铝碳酸镁;  三联疗法;  幽门螺杆菌;  消化性溃疡;  Treg/Th17平衡;  幽门螺杆菌根除率
Keywords:
Hydrotalcite;  Triple therapy;  Helicobacter pylori;  Peptic ulcer;  Treg/Th17 balance;  HP eradication rate
分类号:
R 573.1
DOI:
DOI:10.3969/j.issn.1000-7377.2023.05.022
文献标志码:
A
摘要:
目的:探究铝碳酸镁联合三联疗法治疗幽门螺杆菌(HP)阳性消化性溃疡(PU)对HP根除率及Treg/Th17平衡的影响。方法:选取147例HP阳性PU患者,根据随机数字表法将其分为两组,对照组73例,治疗组74例。对照组采用三联疗法治疗,治疗组采用铝碳酸镁联合三联疗法治疗。观察两组患者的HP清除率、复发率、调节性T细胞(Treg)、辅助性T细胞(Th17)、Treg/Th17、白介素17(IL-17)、白介素25(IL-25)、α-防御素、转化生长因子β1(TGF-β1)、胃肠激素及不良反应的发生情况。结果:治疗后6、12个月治疗组的HP清除率分别为68.92%和89.19%,显著高于对照组的46.58%和68.49%(均P<0.05),治疗组的复发率分别为14.86%和4.05%,显著低于对照组的32.88%和17.81%(均P<0.05); 治疗后,两组Treg、Treg/Th17、α-防御素以及生长抑素(SS)水平均高于治疗前,且治疗组上述各指标水平均显著高于对照组(均P<0.05); 两组Th17、IL-17、IL-25、TGF-β1、胃泌素(GAS)及胃动素(MTL)水平均低于治疗前,且治疗组上述各指标水平显著低于对照组(均P<0.05); 治疗组与对照的不良反应发生率分别为9.18%、11.34%,两组比较差异无统计学意义(P>0.05)。结论:铝碳酸镁联合三联疗法治疗HP阳性PU患者可有效提高HP根除率,调节患者胃肠激素及Treg/Th17平衡,且安全性高。
Abstract:
Objective:To explore the effects of hydrotalcite combined with triple therapy on helicobacter pylori(HP)eradicationrate and Treg/Th17 balance in HP-positive peptic ulcer(PU).Methods:A total of 147 patients with HP-positive PU were enrolled and divided into control group(73 cases,triple therapy)and treatment group(74 cases,hydrotalcite combined with triple therapy)by random number table method.HP eradication rates,recurrence rates,levels of regulatory T cells(Treg),helper T cells(Th17),Treg/Th17,interleukin-17(IL-17),interleukin-25(IL-25),α-defensin,transforming growth factor-β1(TGF-β1)and gastrointestinal hormones,and the occurrence of adverse reactions in the two groups were observed.Results:At 6 months and 12 months after treatment,HP eradication rates in treatment group were 68.92%and 89.19%,significantly higher than 46.58% and 68.49% in control group(all P<0.05); recurrence rates in treatment group were 14.86% and 4.05%,significantly lower than 32.88% and 17.81% in control group(all P<0.05).After treatment,the levels of Treg,Treg/Th17,α-defensin and somatostatin(SS)in the two groups were higher than those before treatment,and the levels of the above indexes in the treatment group were significantly higher than those in the control group(all P<0.05).The levels of Th17,IL-17,IL-25,TGF-β1,gastrin(GAS)and motilin(MTL)in the two groups were lower than those before treatment,and the levels of the above indexes in the treatment group were significantly lower than those in the control group(all P<0.05).The incidence of adverse reactions in the treatment group and the control group was 9.18% and 11.34% respectively,and the difference was not statistically significant(P>0.05).Conclusion:Hydrotalcite combined with triple therapy can effectively improve HP eradication rate,regulate gastrointestinal hormones and Treg/Th17 balance in patients with HP-positive PU,with high safety.

参考文献/References:

[1] Brito BB,Silva FAF,Soares AS,et al.Pathogenesis and clinical management of Helicobacter pylori gastric infection[J].World J Gastroenterol,2019,25(37):5578-5589.
[2] 彭 乐,张 亚,畅海升.瑞巴派特片对治疗幽门螺旋杆菌阳性消化性溃疡效果与复发的影响[J].武警医学,2020,31(9):789-792.
[3] 王 静,薛 蓓,尤强娜,等.延续性干预在加味黄芪建中汤治疗幽门螺杆菌阳性消化性溃疡中的作用[J].陕西中医,2022,43(9):1226-1229.
[4] 张沈晔,林 榕,刘 浩.半夏泻心汤化裁联合兰索拉唑三联疗法治疗HP相关消化性溃疡[J].世界中医药,2020,15(21):3331-3335.
[5] 陈 明,季红莉,路 琴,等.蒲元和胃胶囊联合铝碳酸镁与奥美拉唑治疗幽门螺杆菌阴性胃溃疡疗效及对患者血清学指标的影响[J].药物流行病学杂志,2021,30(3):155-158.
[6] 中华消化杂志编委会.消化性溃疡诊断与治疗规范(2016年,西安)[J].中华消化杂志,2016,36(8):508-513.
[7] 杨 荔,戴 蒙,唐亚萍,等.归脾汤合失笑散加味联合西药治疗消化性溃疡疗效研究[J].陕西中医,2021,42(3):319-322.
[8] Okimoto T,Kodama M,Murakami K.Helicobacter pylori and peptic ulcer[J].Nihon Shokakibyo Gakkai Zasshi,2021,118(10):920-926.
[9] 原 宁,宁 萍.微生态制剂联合奥美拉唑序贯治疗幽门螺旋杆菌阳性消化性溃疡效果及对患儿丙二醛、转化生长因子β1蛋白水平和肠道菌群的影响[J].陕西医学杂志,2021,50(4):472-475.
[10] 王 平,潘爱欢,罗先桃,等.伏诺拉生联合阿莫西林+克拉霉素治疗幽门螺杆菌感染的消化性溃疡的疗效及安全性研究[J].医学临床研究,2022,39(5):785-787.
[11] 樊冬杰,黄玉伟.铝碳酸镁联合四联疗法治疗幽门螺杆菌感染并十二指肠溃疡 120例临床观察[J].安徽医药,2020,24(2):393-397.
[12] 王江鹏,李锋同.营养支持联合奥美拉唑三联疗法对消化性溃疡患儿血清IL-18、IFN-γ、TNF-α水平及Treg/Th17免疫平衡的影响[J].临床误诊误治,2019,32(6):27-32.
[13] 郭艳红,姚青林,张雪丽,等.雌激素对消化性溃疡模型小鼠组织损伤的影响及相关机制研究[J].川北医学院学报,2020,35(4):555-558,567.
[14] 张彦亭,杨振威,原姗姗,等.不同分型幽门螺杆菌感染消化性溃疡患者血清胃蛋白酶原、共刺激分子CD40、α防御素表达及检测意义[J].陕西医学杂志,2020,49(10):1310-1313.
[15] 赵 冰,刘 巍,刘 丹.消化性溃疡并发上消化道出血患者CD4+、CD25+、IL-17、TGF-β水平的变化[J].标记免疫分析与临床,2021,28(8):1292-1295.
[16] 高 巍,姚红娟.奥美拉唑联合铝碳酸镁治疗胃溃疡合并胃出血的临床研究[J].山西医药杂志,2020,49(8):1001-1003.
[17] 刘宏伟,黄玉洁,杨剑英,等.铝碳酸镁、兰索拉唑、阿莫西林、呋喃唑酮四联疗法治疗幽门螺杆菌相关性胃溃疡的效果及安全性评价[J].中国综合临床,2020,36(1):22-27.
[18] 程大伟,赵太云.加减黄芪建中汤联合奥美拉唑对消化性溃疡患者消化道激素及炎症因子的影响[J].世界中西医结合杂志,2022,17(5):1005-1008,1012.
[19] 赵丽娟,武建军,云宇婷,等.荆花胃康胶丸联合标准四联疗法对HP相关十二指肠溃疡患者血清肽类胃肠激素、胃蛋白酶原和炎症介质的影响[J].现代生物医学进展,2022,22(17):3314-3318.
[20] 贾 燕,潘元明,盛剑秋,等.多中心临床观察铝碳酸镁四联与铋剂四联根除幽门螺杆菌的疗效及安全性[J].胃肠病学和肝病学杂志,2022,31(6):648-655.

备注/Memo

备注/Memo:
基金项目:四川省教育厅科研项目(16ZB0534)
更新日期/Last Update: 2023-05-05